• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    SC 13G/A 1 ef20037941_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    BiomX Inc.
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    09090D301
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages
    Page 1 of 8 Pages
    Exhibit Index: Page 7



    CUSIP No. 09090D301
    Page 2 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    John H. Burbank III
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    510,205 (1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    510,205 (1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    510,205 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.9% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     
    (1) See Items 2 and 4


    CUSIP No. 09090D301
    Page 3 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Nimble Ventures, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    510,205 (1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    510,205 (1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    510,205 (1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    2.9% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    (1) See Items 2 and 4


    CUSIP No. 09090D301
    Page 4 of 8 Pages
    Item 1(a).
    Name of Issuer:

    BiomX Inc. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    708 Quince Orchard Road, Suite 205, Gaithersburg, MD 20878

    Item 2(a).
    Name of Person Filing:

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):


    i.
    John H. Burbank III (“Mr. Burbank”); and

    ii.
    Nimble Ventures, LLC (“Nimble Ventures”).

    This Statement on Schedule 13G relates to Shares held directly by Nimble Ventures. Mr. Burbank is the control person of Nimble Ventures and, in such capacity, may be deemed to indirectly beneficially own the Shares that Nimble Ventures directly beneficially owns.

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: c/o Nimble Ventures, LLC, 1 Letterman Drive, Building A, Suite 4900, San Francisco, CA 94129.

    Item 2(c).
    Citizenship:

    Mr. Burbank is a citizen of the United States of America. Nimble Ventures is a Delaware limited liability company.

    Item 2(d).
    Titles of Classes of Securities:

    Common Stock, par value $0.0001 per share (the “Shares”)

    Item 2(e).
    CUSIP Number:

    09090D301

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

    This Item 3 is not applicable.

    Item 4.
    Ownership:

    Item 4(a).
    Amount Beneficially Owned:

    As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of 510,205 Shares.

    Item 4(b).
    Percent of Class:

    As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 2.9% of the Shares outstanding.

    The percentages set forth herein are calculated based on 17,895,844 Shares outstanding as of August 12, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2024, as adjusted for the one-for-ten reverse stock split of the Shares that was effected on August 26, 2024, as reported in the Issuer’s Form 8-K filed with the SEC on August 16, 2024.


    CUSIP No. 09090D301
    Page 5 of 8 Pages
    Item 4(c).
    Number of Shares as to which such person has:


    Mr. Burbank and Nimble Ventures
     

    (i) Sole power to vote or direct the vote:
    0


    (ii) Shared power to vote or direct the vote:
    510,205


    (iii) Sole power to dispose or direct the disposition of:
    0


    (iv) Shared power to dispose or direct the disposition of:
    510,205


    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    This Item 6 is not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See disclosure in Item 2(a) hereof.

    Item 8.
    Identification and Classification of Members of the Group.

    This Item 8 is not applicable.

    Item 9.
    Notice of Dissolution of Group.

    This Item 9 is not applicable.

    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 09090D301
    Page 6 of 8 Pages
    SIGNATURE

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 4, 2024
     

     

    JOHN H. BURBANK III


     

    By:
    /s/ John H. Burbank III

     

    NIMBLE VENTURES, LLC

     

    By:
    /s/ John H. Burbank III

    Name:
    John H. Burbank III
      Title: Control Person


    CUSIP No. 09090D301
    Page 7 of 8 Pages
    EXHIBIT INDEX

    Exhibit
    Page No.

     
    A – Joint Filing Agreement
    8


    CUSIP No. 09090D301
    Page 8 of 8 Pages
    EXHIBIT A

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of BiomX Inc. dated as of November 4, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

    Dated: November 4, 2024
     

     

    JOHN H. BURBANK III

       

    By:
    /s/ John H. Burbank III

       

    NIMBLE VENTURES, LLC



    By:
    /s/ John H. Burbank III

    Name:
    John H. Burbank III

    Title: Control Person



    Get the next $PHGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Financials

    Live finance-specific insights

    See more
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company's website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expec

      3/19/25 12:35:31 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

      NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure

      4/1/25 6:30:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Telum Therapeutics appoints Dr. Subhendu Basu as CEO

      Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

      3/19/24 5:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

      10/18/23 8:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

      11/16/21 9:23:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

      10/19/21 8:36:54 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on BiomX with a new price target

      HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

      10/18/21 12:27:44 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by BiomX Inc.

      SCHEDULE 13G - BiomX Inc. (0001739174) (Subject)

      5/8/25 7:39:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BiomX Inc.

      424B3 - BiomX Inc. (0001739174) (Filer)

      4/24/25 8:47:36 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by BiomX Inc.

      EFFECT - BiomX Inc. (0001739174) (Filer)

      4/24/25 12:15:07 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by *Director by Deputization Flynn James E

      4 - BiomX Inc. (0001739174) (Issuer)

      4/23/25 5:49:02 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 4 filed by Director Merril Gregory Louis

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:24:29 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Development Officer Bassan Merav was granted 79,597 shares (SEC Form 4)

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:11:31 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/13/24 5:14:46 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/4/24 4:05:35 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      10/28/24 4:01:32 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care